Defining Optimal Transitions of Care in Advanced Kidney Disease: Conservative Management vs. Dialysis Approaches

定义晚期肾病护理的最佳转变:保守治疗与透析方法

基本信息

  • 批准号:
    10436989
  • 负责人:
  • 金额:
    $ 64.9万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-09-15 至 2025-04-30
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY/ABSTRACT The 1972 Medicare End-Stage Renal Disease (ESRD) program has led to near-universal access to dialysis in order to extend the survival of advanced chronic kidney disease (CKD) patients progressing to ESRD. Each year ~120,000 patients in the US transition to dialysis as the dominant yet costly treatment paradigm for uremic, biochemical, and volume derangements. However, in the past 4½ decades, there has been little progress or innovation in developing patient-centered treatment options for advanced CKD beyond dialysis. Pioneering research led by our team under the NIH U01 “Transitions of Care in CKD” (TCCKD) United States Renal Data System (USRDS) Special Study Center have shown that transition to dialysis is associated with 1) high mortality particularly in the 1st year of treatment, 2) frequent hospitalizations, 3) poor health-related quality of life (HRQOL), 4) loss of independence, 5) functional decline, and 6) high withdrawal dates, particularly in elderly and comorbid patients. This has prompted rising interest and pressing urgency for conservative dialysis-free management as an alternative treatment option. Yet this strategy remains under-utilized due to major uncertainties regarding 1) the comparative effectiveness of conservative management vs. dialysis on hard outcomes and patient-centered endpoints, and 2) which patients will benefit from dialysis-free treatment. Our Multiple-PI R01 proposal will address these knowledge gaps by using innovative longitudinal data sources from two of the largest US integrated healthcare systems, namely OptumLabs (United Healthcare) and national Veterans Affairs (VA) data linked to Medicare and USRDS resources (2007-18), paired with a well- defined prospective CKD cohort in the largest study of conservative management vs. dialysis transition to date. Using propensity score matching, Aim 1 will examine associations of conservative management vs. dialysis transition with mortality and hospitalization (co-primary outcomes), and skilled nursing facility placement, intensive care admissions, and healthcare costs (secondary outcomes) in two large OptumLabs and VA cohorts each with >0.5 million advanced CKD (eGFR <25ml/min/1.73m2) patients. In these two cohorts, Aim 2 will develop clinical prognostic models that predict an individual’s likelihood of survival and hospitalization with conservative management vs. dialysis. In a prospective cohort of 116 stage 4-5 CKD patients, Aim 3 will compare the impact of conservative management vs. dialysis preparation on the longitudinal trajectory of HRQOL (primary outcome) and physical performance/activity, symptoms, and nutrition (secondary outcomes) using rigorous protocolized data collection with validated instruments. Our findings will have substantial impact on patient care and policy by 1) expanding patient-centered treatment options for the vast CKD population, 2) generating rigorous evidence for clinical guidelines by identifying which patients are optimal candidates for conservative management, and 3) informing clinical practice models aspiring to provide dialysis-free treatment as an approach aligned with patient choice based on the US Advancing American Kidney Health Initiative.
项目摘要/摘要 1972年的Medicare终末期肾脏疾病(ESRD)计划已导致透析几乎通用 为了扩展晚期慢性肾脏疾病(CKD)患者的生存率。每个 美国在美国向透析过渡的120,000名患者是主要但昂贵的治疗范例 尿毒症,生化和体积演变。但是,在过去的4½十年中,几乎没有 在透析以外的晚期CKD开发以患者为中心的治疗方案的进展或创新。 我们团队在NIH U01“ CKD的过渡”(TCCKD)美国领导的开创性研究 肾脏数据系统(USRDS)特别学习中心表明,向透析的过渡与1相关 高死亡率,特别是在治疗的第一年,2)经常住院,3)与健康相关的质量差 生命(HRQOL),4)失去独立性,5)功能下降,6)高戒断日期,特别是在 老年人和合并症患者。这促使人们的兴趣不断上升,并紧迫的保守派紧迫 无透析管理作为替代治疗选择。然而,由于 关于1)保守管理与透析的比较有效性 硬结局和以患者为中心的终点,以及2)患者将从无透析治疗中受益。 我们的多PI R01提案将通过使用创新的纵向数据来解决这些知识差距 来自美国两个最大的综合医疗保健系统的来源,即optumlabs(联合医疗保健)和 与Medicare和USRDS Resources(2007-18)相关的国家退伍军人事务(VA)数据,与一个很好的 迄今为止,保守管理与透析过渡的最大研究中定义了预期的CKD队列。 使用倾向得分匹配,AIM 1将检查保守管理与透析的关联 死亡率和住院过渡(共同成果)和熟练的护士设施, 两个大型optumlabs和VA的重症监护入院和医疗保健费用(次要结果) 每人均与> 50万晚期CKD(EGFR <25ml/min/1.73m2)患者。在这两个队列中,目标2 将开发临床预后模型,以预测个人的生存和住院可能性 保守管理与透析。在预期的116阶段4-5 ckd患者中,AIM 3将 比较保守管理与透析准备对纵向轨迹的影响 HRQOL(主要结果)和身体表现/活动,症状和营养(次要结果) 使用严格的协议数据收集和经过验证的仪器。我们的发现将产生重大影响 关于患者护理和政策的1)扩大了大量CKD人群中心的以患者为中心的治疗方案,2) 通过确定哪些患者是最佳候选者来为临床准则生成严格的证据 保守管理和3)通知渴望提供无透析治疗的临床实践模型 作为一种与美国肾脏健康计划的患者选择保持一致的方法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

暂无数据

数据更新时间:2024-06-01

Kamyar Kalantar-Z...的其他基金

Plant-Focused Nutrition in Patients with Diabetes and Chronic Kidney Disease (PLAFOND Study): A Pilot/Feasibility Study
糖尿病和慢性肾病患者的植物性营养(PLAFOND 研究):试点/可行性研究
  • 批准号:
    10586677
    10586677
  • 财政年份:
    2023
  • 资助金额:
    $ 64.9万
    $ 64.9万
  • 项目类别:
Continuous Glucose Monitoring in Dialysis Patients to Overcome Dysglycemia Trial (CONDOR TRIAL)
透析患者连续血糖监测克服血糖异常试验(CONDOR TRIAL)
  • 批准号:
    10587470
    10587470
  • 财政年份:
    2023
  • 资助金额:
    $ 64.9万
    $ 64.9万
  • 项目类别:
Incremental Hemodialysis for Veterans in the First Year of Dialysis (IncHVets): A Pragmatic, Multi-Center, Randomized Controlled Trial
退伍军人透析第一年增量血液透析 (IncHVets):一项务实、多中心、随机对照试验
  • 批准号:
    10486289
    10486289
  • 财政年份:
    2022
  • 资助金额:
    $ 64.9万
    $ 64.9万
  • 项目类别:
Defining Optimal Transitions of Care in Advanced Kidney Disease: Conservative Management vs. Dialysis Approaches
定义晚期肾病护理的最佳转变:保守治疗与透析方法
  • 批准号:
    10264944
    10264944
  • 财政年份:
    2020
  • 资助金额:
    $ 64.9万
    $ 64.9万
  • 项目类别:
Racial and Cardiovascular Risk Factor Anomalies in CKD
CKD 中的种族和心血管危险因素异常
  • 批准号:
    8635349
    8635349
  • 财政年份:
    2013
  • 资助金额:
    $ 64.9万
    $ 64.9万
  • 项目类别:
Comparative Effectiveness of Home Hemodialysis versus Kidney Transplantation in t
家庭血液透析与肾移植在治疗中的效果比较
  • 批准号:
    8741928
    8741928
  • 财政年份:
    2013
  • 资助金额:
    $ 64.9万
    $ 64.9万
  • 项目类别:
Racial and Cardiovascular Risk Factor Anomalies in CKD
CKD 中的种族和心血管危险因素异常
  • 批准号:
    8532600
    8532600
  • 财政年份:
    2013
  • 资助金额:
    $ 64.9万
    $ 64.9万
  • 项目类别:
Racial and Cardiovascular Risk Factor Anomalies in CKD
CKD 中的种族和心血管危险因素异常
  • 批准号:
    8811934
    8811934
  • 财政年份:
    2013
  • 资助金额:
    $ 64.9万
    $ 64.9万
  • 项目类别:
Comparative Effectiveness of Home Hemodialysis versus Kidney Transplantation in t
家庭血液透析与肾移植在治疗中的效果比较
  • 批准号:
    8652787
    8652787
  • 财政年份:
    2013
  • 资助金额:
    $ 64.9万
    $ 64.9万
  • 项目类别:
Comparative Effectiveness of Dialysis Modalities
透析方式的比较有效性
  • 批准号:
    8713986
    8713986
  • 财政年份:
    2012
  • 资助金额:
    $ 64.9万
    $ 64.9万
  • 项目类别:

相似海外基金

Developing Real-world Understanding of Medical Music therapy using the Electronic Health Record (DRUMMER)
使用电子健康记录 (DRUMMER) 培养对医学音乐治疗的真实理解
  • 批准号:
    10748859
    10748859
  • 财政年份:
    2024
  • 资助金额:
    $ 64.9万
    $ 64.9万
  • 项目类别:
DULCE (Diabetes InqUiry Through a Learning Collaborative Experience)
DULCE(通过学习协作体验进行糖尿病查询)
  • 批准号:
    10558119
    10558119
  • 财政年份:
    2023
  • 资助金额:
    $ 64.9万
    $ 64.9万
  • 项目类别:
University of Louisville Biomedical Integrative Opportunity for Mentored Experience Development -PREP (UL-BIOMED-PREP)
路易斯维尔大学生物医学综合指导经验开发机会 -PREP (UL-BIOMED-PREP)
  • 批准号:
    10557638
    10557638
  • 财政年份:
    2023
  • 资助金额:
    $ 64.9万
    $ 64.9万
  • 项目类别:
Differences in Hospital Nursing Resources among Black-Serving Hospitals as a Driver of Patient Outcomes Disparities
黑人服务医院之间医院护理资源的差异是患者结果差异的驱动因素
  • 批准号:
    10633905
    10633905
  • 财政年份:
    2023
  • 资助金额:
    $ 64.9万
    $ 64.9万
  • 项目类别:
Enhancing Mentoring of Diverse Early Career Researchers
加强对多元化早期职业研究人员的指导
  • 批准号:
    10797836
    10797836
  • 财政年份:
    2023
  • 资助金额:
    $ 64.9万
    $ 64.9万
  • 项目类别: